British journal of pharmacology · 2026
Cyclodextrin-based delivery of Annexin A1 mimetic Ac2-26 enhances anti-inflammatory effect and prevents dengue-induced lethality combined with antiviral therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martins Jenniffer Ramos, Batista Viviane Lima, Ramos Laís Gomes, Queiroz-Junior Celso Martins, da Fonseca Talita Cristina Martins, Dias Angélica Samer Lallo, Silva Leticia Soldati, da Silva Santos Felipe Rocha, de Castro Santos Ana Luiza, Lula Ivana Silva, Rocha Felipe Emanuel Oliveira, Pereira Jéssica Aparecida Barsalini, Lara Edvaldo Souza, Souza Thiago Moreno L, Sousa Lirlândia Pires, Teixeira Mauro Martins, Guimarães Pedro Pires Goulart, Costa Vivian Vasconcelos
Аннотация
BACKGROUND AND PURPOSE: Severe dengue is characterised by systemic inflammation, cytokine storm, vascular leakage and haemorrhagic manifestations, largely driven by the host immune response to dengue virus (DENV) infection. Despite its burden, no licensed antivirals or host-directed therapies are currently available. Our group has previously identified Annexin A1 (AnxA1) as an endogenous regulator of inflammation in dengue. Treatment with the AnxA1 peptidomimetic, Ac2-26, improved clinical outcomes in murine models of severe dengue by promoting resolution of inflammation without affecting viral control.
EXPERIMENTAL APPROACH: To explore new delivery strategies, we developed a novel formulation of Ac2-26 complexed with hydroxypropyl-β-cyclodextrin (CDX-Ac2-26).
KEY RESULTS: In DENV-2-infected A129 mice, both intraperitoneal and oral CDX-Ac2-26 improved clinical scores and reversed thrombocytopenia. Notably, CDX-Ac2-26 reduced mast cell degranulation, MCPT-1 plasma levels and CCL2 expression in spleen, with no effect on viral titres, indicating a host-targeted mechanism and overcoming the anti-inflammatory effects of the free peptide. Intraperitoneal administration achieved the same efficacy as oral dosing with only one-third of the dose. Importantly, the combination of CDX-Ac2-26 with the antiviral nucleotide analogue sofosbuvir fully prevented disease and mortality in infected mice, highlighting a combinatorial effect between host-directed and antiviral therapies.
CONCLUSION AND IMPLICATIONS: These findings underscore the therapeutic potential of anti-inflammatory/pro-resolving strategies in severe dengue and support the development of CDX-Ac2-26 as a novel adjunctive treatment. Combining anti-inflammatory and antiviral approaches may enhance efficacy and reduce treatment-associated toxicity, offering a promising path for clinical translation.
EXPERIMENTAL APPROACH: To explore new delivery strategies, we developed a novel formulation of Ac2-26 complexed with hydroxypropyl-β-cyclodextrin (CDX-Ac2-26).
KEY RESULTS: In DENV-2-infected A129 mice, both intraperitoneal and oral CDX-Ac2-26 improved clinical scores and reversed thrombocytopenia. Notably, CDX-Ac2-26 reduced mast cell degranulation, MCPT-1 plasma levels and CCL2 expression in spleen, with no effect on viral titres, indicating a host-targeted mechanism and overcoming the anti-inflammatory effects of the free peptide. Intraperitoneal administration achieved the same efficacy as oral dosing with only one-third of the dose. Importantly, the combination of CDX-Ac2-26 with the antiviral nucleotide analogue sofosbuvir fully prevented disease and mortality in infected mice, highlighting a combinatorial effect between host-directed and antiviral therapies.
CONCLUSION AND IMPLICATIONS: These findings underscore the therapeutic potential of anti-inflammatory/pro-resolving strategies in severe dengue and support the development of CDX-Ac2-26 as a novel adjunctive treatment. Combining anti-inflammatory and antiviral approaches may enhance efficacy and reduce treatment-associated toxicity, offering a promising path for clinical translation.